secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0000950170-25-031324
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics updates corporate presentation highlighting pipeline progress and clinical data
--------------------------------------------------------------------------------

- [212Pb]VMT-α-NET Phase 1/2a for neuroendocrine tumors shows anti-tumor activity with no renal decline.
- Melanoma program [212Pb]VMT01 Phase 1/2a ongoing; safety profile detailed in presentation.
- PSV359 targeting FAP-α active on tumor and stroma; pre-targeting platform also described.
- On-demand order fulfillment at regional sites as part of supply chain and manufacturing infrastructure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000095017025031324/0000950170-25-031324-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000095017025031324/catx-20250303.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-031324

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer